BiotechTube
NFL Biosciences

NFL Biosciences

Montpellier, France· Est.
nflbiosciences.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $8.2M

Overview

NFL Biosciences is a clinical-stage biotech focused on botanical drug candidates for substance addictions, including tobacco, alcohol, and cannabis. Its most advanced program, NFL-101 for smoking cessation, has completed three clinical studies, with a related candidate, NFL-102, also in clinical progress. The company went public in 2021, raising €14 million, and leverages a capital-efficient, outsourced research model while holding five patent families to protect its innovative approach.

AddictionSmoking CessationAlcohol Use Disorder

Technology Platform

Botanical drug discovery and development platform focused on extracting and developing active pharmaceutical ingredients from plants for the treatment of addictions.

Funding History

1
Total raised:$8.2M
IPO$8.2M

Opportunities

Large, underserved global markets for smoking cessation and alcohol use disorder treatments present a multi-billion dollar opportunity.
A novel, botanical-based mechanism of action could differentiate from existing therapies and address patient needs for alternatives with better tolerability.
The company's capital-efficient, partnership-focused model could allow it to capture value without building large commercial infrastructure.

Risk Factors

High clinical development risk associated with novel botanical candidates and unproven mechanisms in addiction.
Reliance on future financing to continue operations, with potential dilution for shareholders.
Intense competition from both existing pharmacotherapies and new modalities in development for addiction treatment.

Competitive Landscape

The smoking cessation market is competitive, dominated by NRTs, varenicline (Chantix), and bupropion. NFL's candidates compete by offering a non-nicotine, immune-modulating approach. In alcohol use disorder, the market has few drugs (naltrexone, acamprosate, disulfiram), creating an opening for new entrants. NFL faces competition from other biotechs exploring novel mechanisms for addiction.

More companies in Small Molecule Drugs →More companies in France →